12006 Background: Ima has been reported to increase T U of other chemotherapy drugs and to reduce interstitial fluid pressure (IFP) in experimental animals. Poplin et al performed a phase 1 analysis of Ima plus Ge in solid tumors (AACR 95:405, 2004). We tested ImaGe to determine the T PK and PD effects of Ima, Ge, and the ImaGe combination using DCE-MRI and MRS. Methods: Patients (pt) with measurable and MRI-imagible refractory solid T possibly responsive to Ge were randomized to receive either: one course of Ima with PK/PD, followed by one course of Ge with PK/PD, followed by the combination ImaGe; or one course of Ge with PK/PD followed by one course of Ima with PK/PD, followed by ImaGe. Ge was given at 900 mg/m2 IV over 30 min. for PK/PD and at 10 mg/m2/min. for continued therapy. Ima was given at 400 mg daily for 5 d. with Ge given on day 3. Doses were adjusted for toxicity. T V was measured by the use of DCE-MRI, as described previously (AACR 95:490,2004), where the initial contrast accumulation rate (ICAR) was calculated as the slope of the influx curve, and the delayed contrast accumulation rate (DCAR), measured between 2–20 min post contrast administration, as an approximation of IFP. Ge U was measured by serial 19F-MRS for ∼ 1hr post Ge administration. Results: To date 7 pts have been evaluated for the trial. Two pts have entered the trial and completed one cycle of therapy for PK/PD evaluation. Ima produced moderate nausea in both pts. Other toxicity was negligible. In the first pt Ima produced an 18% increase in the ICAR and a 72% increase in the DCAR but there was no significant change observed in the Ge uptake. In the second pt, Ima produced a 60% increase in the ICAR and a 21% increase in the DCAR. Neither of the 2 pts responded to treatment. Further pts are under study and their PK/PD results will be presented. Conclusions: PK and PD can be measured using DCE MRI together with MRS to determine the clinical affects of Ima, Ge, and the Ima-Ge combination. Current results indicate that Ima has a measurable effect on T V, but its relation to drug U and pt response require further pt evaluations to be definitive. [Table: see text]